/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

D

D-Y. Oh

Seoul National University(KR)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

88

Papers

1.2K

Citations

16

h-index

20

i10-index

D-Y. Oh is an academic researcher from Seoul National University. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Cholangiocarcinoma and Gallbladder Cancer Studies & Colorectal Cancer Treatments and Studies. The author has an h-index of 16, co-authored 75 publications.

Research Topics

Gastric Cancer Management and Outcomes Cholangiocarcinoma and Gallbladder Cancer Studies Colorectal Cancer Treatments and Studies HER2/EGFR in Cancer Research Cancer Immunotherapy and Biomarkers

Papers by this author

works

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

2019 · The Lancet Oncology · 129 citations

https://doi.org/10.1016/s1470-2045(19)30565-0

Yeon Hee Park Tae‐Yong Kim Gun Min Kim Seok Yun Kang

1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)

2024 · Annals of Oncology · 16 citations

https://doi.org/10.1016/j.annonc.2024.08.1467

Y. Y. Janjigian Hanneke W.M. van Laarhoven Sun Young Rha V S Kozlov

606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors

2024 · Annals of Oncology · 14 citations

https://doi.org/10.1016/j.annonc.2024.08.673

Funda Meric‐Bernstam Yoichi Naito Stéphanie Gaillard T. Shimoi

1437P Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up

2024 · Annals of Oncology · 5 citations

https://doi.org/10.1016/j.annonc.2024.08.1503

Marcia Cruz‐Correa D-Y. Oh Ken Kato Josep Tabernero

1532TiP Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study

2024 · Annals of Oncology · 4 citations

https://doi.org/10.1016/j.annonc.2024.08.1595

Won Park Eileen M. O’Reilly Li Cp D-Y. Oh

40O Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results

2025 · ESMO Open · 2 citations

https://doi.org/10.1016/j.esmoop.2025.104199

E. Calvo Víctor Moreno D-Y. Oh Min‐Hee Ryu

Research topics

topics

Gastric Cancer Management and Outcomes

Cholangiocarcinoma and Gallbladder Cancer Studies

Colorectal Cancer Treatments and Studies

HER2/EGFR in Cancer Research

Cancer Immunotherapy and Biomarkers

Chat about Author

Papers

Chat

Click to start Chat